Photo: Biolux Research
Vancouver-based orthodontic device company Biolux Research recently announced it has raised $14 million in Series A funding led by Venrock. Correlation Ventures, several insiders, and other investors also participated in this round.
“The orthodontics industry is large, growing, and evolving – and we believe Biolux can be a vital part of that growth and transformation. Biolux has developed an innovative, evidence-based product that meaningfully transforms orthodontists’ practice economics and creates a fundamentally more satisfying consumer experience,” said Venrock Partner Cami Samuels.
Biolux manufactures OrthoPulse — which is an FDA cleared orthodontic device that is currently being sold in the U.S., Europe, and Asia. OrthoPulse is a non-invasive device that can be used for 10 minutes each day to accelerate orthodontic treatment by up to 50%. And it leads to better smiles with significantly less pain for both aligner and fixed appliance treatment modalities.
Biolux also announced that David Thrower has been named as CEO of the company. Thrower started his career at Bain & company. And Thrower spent most of his career driving growth in businesses that are at the intersection of the consumer and medical devices spaces. Prior to joining Biolux, Thrower held the CEO position BAROnova (2016-2018), Asante Solutions (2012-2015), and InSound Medical (2005-2011).
“I am honored to be appointed as CEO of Biolux. It is a privilege to be part of a company that is revolutionizing orthodontic care. The proprietary Biolux technology creates significant value for the orthodontist and consumer alike,” added Thrower. “I am looking forward to leading the Biolux team in making OrthoPulse a part of the standard of orthodontic care around the globe by delivering better smiles in less time with more patient ”
Biolux Research’s patented technologies were developed to enhance clinical outcomes, increase patient comfort, and dramatically reduce treatment time while utilizing a non-invasive approach.
“This investment by a premier venture capitalist as well as the successful addition of an accomplished CEO to the Biolux team is an important validation of the OrthoPulse technology. We look forward to this exciting new chapter of Biolux’s growth,” explained Biolux CFO Jay Chen.
